Human Immunodeficiency Virus (HIV)
Conditions
Keywords
Human Immunodeficiency Virus, HIV, Etravirine, Darunavir, Prezista, Intelence, Ritonavir, INROADS
Brief summary
This study is a Phase II single arm, open-label, multicenter, study of 50 human immunodeficiency virus-1 (HIV) infected adult patients, all of whom will receive etravirine (ETR) 400mg and DRV/r 800/100mg each given orally once daily. This trial is designed to evaluate the efficacy of the aforementioned ARV regimen, as measured by the percentage of patients with HIV RNA \<50 copies/mL at 48 weeks, in early treatment-experienced HIV-infected patients. In addition to general safety parameter measurements, this trial will also assess changes in metabolic, inflammatory, immune restoration, and bone markers. Screening will occur over a 6-week period. The primary endpoint will be assessed at Week 48, and the treatment period is 48 weeks. The end of study endpoint will be met by either completing the Week 48 visit, or by early termination from the study for any reason.
Detailed description
This study is a Phase II single arm, open-label, multicenter, (all people involved know the identity of the intervention) study of 50 HIV-1 infected adult patients, all of whom will receive ETR 400mg and darunavir (DRV)/r 800/100mg each given orally once daily. This trial is designed to evaluate the efficacy of the aforementioned ARV regimen, as measured by the percentage of patients with HIV ribonucleic acid (RNA) \<50 copies/mL at 48 weeks, in early treatment-experienced HIV-infected patients. In addition to general safety parameter measurements, this trial will also assess changes in metabolic, inflammatory, immune restoration, and bone markers. Screening will occur over a 6-week period. The trial schedule includes a Baseline Visit (Day 1), Open-label Treatment Phase (Weeks 4, 8, 12, 16, 20, 24, 30, 36, 42, 48/ Early Withdrawal) and a Post-treatment Phase (4 Week Follow-Up) visit. In addition, all patients will have two pharmacokinetic (PK) samples drawn at Weeks 4 and 24, A single PK sample will be drawn at Weeks 12, 36, and 48 (or early withdrawal visit). There will also be a substudy conducting 24 hour intensive PK at week 4 for a subset of patients. For patients who consent, genotyping for CYP2C9 and CYP2C19 will be performed at Baseline. A Modified Medication Adherence Self-Report Inventory (M-MASRI) questionnaire will be collected, which is a patient-reported survey to assess adherence to medication taking. The primary endpoint will be assessed at Week 48, and the treatment period is 48 weeks. The end of study endpoint will be met by either completing the Week 48 visit, or by early termination from the study for any reason. ETR 400mg once daily for 48 weeks and DRV 800mg once daily for 48 weeks.
Interventions
DRUGEtravirine
400mg once daily orally for 48 weeks
DRUGRitonavir
100mg once daily orally for 48 weeks
DRUGDarunavir
800mg once daily orally for 48 weeks
Sponsors
Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA
Tibotec, Inc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients, aged 18 years or above * Patients with documented HIV-1 infection * On current HAART regimen for at least 12 weeks continuous duration at screening, and with an HIV-1 plasma viral load above 500 HIV-1 RNA copies/mL by site's currently utilized viral load assay (Note: For the purposes of this study, HAART is defined as treatment with a combination of 3 or more HIV antiretroviral medications from at least 2 different classes of medications (NRTIs, NNRTIs, PIs, integrase inhibitors, CCR5 antagonists, fusion inhibitors)) * No more than 2 previous virologic failures while on PI-containing HAART regimens where virologic failure is generally defined as either a lack of suppression of the subjects' viral load to lower limit of quantification (per standard assay historically used in care) after 24 weeks of treatment or, rebound of a previously suppressed viral load (undetectable per investigator's standard of care) to detectable limits and without demonstrated re-suppression on the same regimen * Demonstrated phenotypic sensitivity to both etravirine and darunavir based on resistance testing at Screening (FC= 2.9 for etravirine and FC = 10.0 for darunavir using the PhenoSense GT) * The absence of all of the following Resistance Associated Mutations (RAMS) at baseline: For Darunavir: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V * For Etravirine: L100I, E138A, I167V, V179D, V179F, Y181I, Y181V, G190S * 7\. CD4 count = 50 cells/mm3.
Exclusion criteria
* Primary HIV-1 infection * Previously documented HIV-2 infection * Use of disallowed concomitant therapy Any condition (including but not limited to alcohol and drug use), which, in the opinion of the investigator, could compromise the patient's safety or adherence to the protocol * Life expectancy less than 6 months according to the judgment of the investigator * Patient has any currently active AIDS defining illness (Category C conditions according to the Center for Disease Control \[CDC\] Classification System for HIV infection 1993 * with the following exceptions, which must be discussed with the sponsor prior to enrollment: Stable cutaneous Kaposi's Sarcoma (i.e., no pulmonary or gastrointestinal involvement other than oral lesions) that is unlikely to require any form of systemic therapy during the trial period * Wasting syndrome due to HIV infection if, in the investigator's opinion, it is not actively progressive and its treatment does not require hospitalization or compromise the patient's safety or compliance to adhere to trial-related procedures. If the patient is on maintenance therapy (which may include Growth Hormone, appetite stimulants and anabolic steroids) for previously diagnosed wasting syndrome, he/she may be eligible for the trial. Note: An AIDS defining illness not clinically stabilized for at least 30 days will be considered clinically active. Note: Primary and secondary prophylaxis for an AIDS defining illness is allowed in case the medication used is not part of the disallowed medications * Any active clinically significant disease (e.g., pancreatitis, cardiac dysfunction) or findings during screening of medical history, laboratory or physical examination that, in the investigator's opinion, would compromise the patient's safety or the outcome of the trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Confirmed Virologic Response (CVR) at Week 48 | Week 48 | CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 8 | Baseline (Day 1) and Week 8 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 12 | Baseline (Day 1) and Week 12 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 16 | Baseline (Day 1) and Week 16 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 20 | Baseline (Day 1) and Week 20 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 24 | Baseline (Day 1) and Week 24 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 30 | Baseline (Day 1) and Week 30 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 4 | Baseline (Day 1) and Week 4 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 42 | Baseline (Day 1) and Week 42 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 48 | Baseline (Day 1) and Week 48 | — |
| Time to Reach First Confirmed Virologic Response | Baseline (Day 1) to Week 48 | CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL. |
| Number of Participants With Virologic Failure | Baseline (Day 1) to Week 48 | Virologic Failure is defined as participant who is a rebounder or a non-responder. Rebounder participant is defined as a participant who is still in the study at Week 12 and first achieves 2 consecutive virologic responses (\<50 copies/mL) followed by 2 consecutive non-responses or a discontinued participant (any reason) for which the last observed time point shows a non-response. Non responder participant is defined as a participant who is still in the study at Week 12 and never achieves 2 consecutive responses. |
| Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48 | Baseline (Day 1) and Week 48 | — |
| Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 36 | Baseline (Day 1) and Week 36 | — |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
The study was conducted between 29 March 2010 and 5 October 2012 and recruited patients from US (17 sites) and Puerto Rico (1 site).
Pre-assignment details
54 participants were treated with Etravirine and Darunavir/ritonavir in this study.
Participants by arm
| Arm | Count |
|---|---|
| ETR + DRV/Rtv Etravirine (ETR) 400mg + Darunavir (DRV) 800mg/Ritonavir (rtv) 100mg once daily orally for 48 weeks | 54 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 4 |
| Overall Study | Lost to Follow-up | 2 |
| Overall Study | Protocol Violation | 3 |
| Overall Study | Reached a virologic endpoint | 4 |
Baseline characteristics
| Characteristic | ETR + DRV/Rtv |
|---|---|
| Age Continuous | 44.4 years STANDARD_DEVIATION 12.82 |
| Region of Enrollment Puerto Rico | 4 participants |
| Region of Enrollment USA | 50 participants |
| Sex: Female, Male Female | 12 Participants |
| Sex: Female, Male Male | 42 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 28 / 54 |
| serious Total, serious adverse events | 3 / 54 |
Outcome results
Primary
Number of Participants With Confirmed Virologic Response (CVR) at Week 48
CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.
Time frame: Week 48
Population: Intent-To-Treat Non-Virologic failure (VF) censored: Participants who took at least one dose of any of the study medications and did not withdraw for reasons other than VF or experienced VF prior to discontinuation. Participants with evaluable data at Week 48
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| ETR + DRV/Rtv | Number of Participants With Confirmed Virologic Response (CVR) at Week 48 | 40 Participants |
Secondary
Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48
Time frame: Baseline (Day 1) and Week 48
Population: Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48 | CD4 | 168 cells/uL | Standard Deviation 153.3 |
| ETR + DRV/Rtv | Change From Baseline in Cluster of Differentiation 4 (CD4+) and Cluster of Differentiation 8 (CD8+) Cell Counts at Week 48 | CD8 | -69 cells/uL | Standard Deviation 289.4 |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 12
Time frame: Baseline (Day 1) and Week 12
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 12
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 12 | -2.18 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 16
Time frame: Baseline (Day 1) and Week 16
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 16
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 16 | -2.29 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 20
Time frame: Baseline (Day 1) and Week 20
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 20
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 20 | -2.27 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 24
Time frame: Baseline (Day 1) and Week 24
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 24
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 24 | -2.17 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 30
Time frame: Baseline (Day 1) and Week 30
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 30
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 30 | -2.28 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 36
Time frame: Baseline (Day 1) and Week 36
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 36
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 36 | -2.24 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 4
Time frame: Baseline (Day 1) and Week 4
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 4
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 4 | -1.77 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 42
Time frame: Baseline (Day 1) and Week 42
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 42
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 42 | -2.29 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 48
Time frame: Baseline (Day 1) and Week 48
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 48
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 48 | -2.29 log10 Copies/mL |
Secondary
Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 8
Time frame: Baseline (Day 1) and Week 8
Population: Intent-to-treat participants who received at least one dose of any of the study medication with evaluable data at Week 8
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| ETR + DRV/Rtv | Change From Baseline in Log10 Plasma Human Immunodeficiency Virus - Type 1 (HIV-1) Viral Load at Week 8 | -2.04 log10 Copies/mL |
Secondary
Number of Participants With Virologic Failure
Virologic Failure is defined as participant who is a rebounder or a non-responder. Rebounder participant is defined as a participant who is still in the study at Week 12 and first achieves 2 consecutive virologic responses (\<50 copies/mL) followed by 2 consecutive non-responses or a discontinued participant (any reason) for which the last observed time point shows a non-response. Non responder participant is defined as a participant who is still in the study at Week 12 and never achieves 2 consecutive responses.
Time frame: Baseline (Day 1) to Week 48
Population: Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications
| Arm | Measure | Value (NUMBER) | Dispersion |
|---|---|---|---|
| ETR + DRV/Rtv | Number of Participants With Virologic Failure | 7 Participants | 6.684 |
Secondary
Time to Reach First Confirmed Virologic Response
CVR is defined as confirmed plasma Viral Load of less than 50 human immunodeficiency virus - type 1 (HIV-1) ribonucleic acid (RNA) copies/mL.
Time frame: Baseline (Day 1) to Week 48
Population: Intent-To-Treat participants enrolled in the study who took at least one dose of any of the study medications
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| ETR + DRV/Rtv | Time to Reach First Confirmed Virologic Response | 82.98 Days | Standard Error 6.684 |